Study EvAluating Genotypes While Using Lucentis 2

Part of paid clinical trials in San Diego, California.

Sponsor
University of California, San Diego
Study ID
NCT01464723
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ranibizumab — DRUG
    Intravitreal injections of 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months.

Study Details

The purpose of the study is to investigate whether the efficacy of Lucentis treatment for exudative age-related macular degeneration is associated with VEGF and HTRA1 DNA polymorphisms

Key Dates

First listed
Nov 3, 2011
Start date
May 31, 2008
Status verified
Jul 2019
Primary completion
Dec 31, 2011
Completion
Jan 31, 2013

Study Design

Enrollment
66 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Lucentis
    Consented, enrolled subjects will receive multiple open-label intravitreally administered 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months.

Primary Outcome Measure

To Determine the Genotype at VEGF and HTRA1 SNPs of Patients Gaining ≥ 0 Letters of Visual Acuity in Response to Ranibizumab Treatment Over a 4 Month Period. [ Time Frame: 5 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Shiley Eye Center, University of California, San DiegoSan DiegoCalifornia92093-

Find similar trials in San Diego, CA

By condition
Age-related macular degeneration
By specialty
OphthalmologyRetina
By research site
Shiley Eye Center, University of California, San Diego· San Diego, CA

Related Studies